Irofulven + capecitabine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Thyroid Cancer
Conditions
Thyroid Cancer
Trial Timeline
Mar 31, 2005 → Aug 31, 2006
NCT ID
NCT00124527About Irofulven + capecitabine
Irofulven + capecitabine is a phase 2 stage product being developed by Eisai for Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00124527. Target conditions include Thyroid Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00124527 | Phase 2 | Completed |
Competing Products
20 competing products in Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 | MBX Biosciences | Phase 2 | 47 |
| 400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | MBX Biosciences | Phase 2 | 47 |
| PCO371 + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| CS-7017 + Paclitaxel | Daiichi Sankyo | Phase 1/2 | 41 |
| efatutazone + paclitaxel | Daiichi Sankyo | Phase 2 | 52 |
| ASP7991 + Cinacalcet + Placebo | Astellas Pharma | Phase 2 | 52 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib + Placebo + Lenvatinib | Eisai | Phase 3 | 77 |
| Lenvatinib + Placebo | Eisai | Phase 3 | 77 |
| Lenvatinib | Eisai | Approved | 85 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Bexarotene | Eisai | Phase 1 | 33 |
| Lenvatinib + Lenvatinib matching placebo | Eisai | Phase 2 | 52 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| LENVATINIB | Eisai | Phase 2 | 52 |
| E7080 capsule | Eisai | Phase 2 | 52 |
| Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort) | Eisai | Phase 2 | 52 |
| Lenvatinib 24 mg | Eisai | Phase 2 | 52 |
| KHK7580 + KRN1493 | Kyowa Kirin | Phase 2/3 | 65 |